SLRX
Salarius Pharmaceuticals Inc
NASDAQ: SLRX · HEALTHCARE · BIOTECHNOLOGY
$0.84
+29.23% today
Updated 2026-01-07
Market cap
$4.92M
P/E ratio
—
P/S ratio
18.12x
EPS (TTM)
$-24.24
Dividend yield
—
52W range
$1 – $25
Volume
2.4M
Salarius Pharmaceuticals Inc (SLRX) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-20.75M | $-32.05M | $-27.72M | $-23.60M | $-11.58M | $-10.31M | $-10.20M | $-17.60M | $-12.85M | $-4.53M |
| Capital expenditures | $265617.00 | $559378.00 | $113498.00 | $2600.00 | $2600.00 | $2600.00 | $3.00 | $1.50M | $3.00 | $0.00 |
| Depreciation | — | — | — | — | — | — | — | — | — | — |
| Stock-based comp | — | — | — | — | — | — | — | — | — | — |
| Free cash flow | $-21.01M | $-32.61M | $-27.84M | $-23.60M | $-11.58M | $-10.31M | $-10.20M | $-19.10M | $-12.85M | $-4.53M |
| Investing cash flow | — | — | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — | — | — |
| Dividends paid | — | $133594.00 | $133594.00 | $133594.00 | $133594.00 | $0.00 | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | $32.83M | — | — | — | $-2.39M | $7.38M | — | — | — | — |
Frequently asked questions
How much free cash flow does SLRX generate?
SLRX produced $-4.53M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.